04.06.2012 - Austrian biotech Nabriva Therapeutics AG has partnered with Forest Laboratories Inc. to develop its antibiotic BC-3781.
Vienna - As part of the deal, Forest will have the exclusive right to acquire Nabriva for the next 12 months. Nabriva will receive US$25m. Forest will also fund and help develop BC-3781 during the period. BC-3781 belongs to a novel class of antibiotics, the pleuromutilins. It is designed to treat severe and drug resistant infections including MRSA, penicillin-resistant Streptococcus pneumonia, Legionella pneumophila, which causes Legionnaires' disease, and Chlamydophila pneumoniae, a major cause of pneumonia.
BC-3781 has potential in both intravenous and oral formulations and the cooperating companies plan to advance it into Phase III testing early next year. Forest said the oral formulation provides an opportunity to treat patients after they leave the hospital and would complement its Teflaro ceftaroline, a cephalosporin antibiotic available only as an intravenous drug.
Nabriva is based in Vienna, and in 2011 it reported positive mid-stage trial results from a Phase IIb study that evaluated BC-3781 as a treatment for acute bacterial and skin structure infections.
23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.
21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.